Feed CDT
Summary
47 / 100 · Bulios Score
Valuation 100Growth -Profitability 41Quality 31Debt 40Stability 11
What speaks for it
- You pay 0.0 USD for 1 USD of yearly profit, little for its sector.
- It bought back its own shares for $106.0K in the last fiscal year, 51% of its market value.
What to watch
- Repaying its net debt would take 4.0 years of operating profit.
- It reports a profit, yet spends more cash than it brings in.
- It earns only 4.5 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E today 0.0
Biotechnology industry median
Today you pay 0.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 61 USD
- Research and development 4.5 USD
- Sales and administration 23 USD
- Taxes and other 5.3 USD
- Net profit 6.3 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 6.3 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $348.7M
Debt $1.32B
Free cash flow over 12 months -$1.29M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Automation Solutions 100%
By region
- UNITED STATES 57%
- Other Countries 28%
- CANADA 6.5%
- GERMANY 4.8%
- CHINA 3.7%
Automation Solutions brings in 100% of revenue.
Segments in detail